150 related articles for article (PubMed ID: 34747637)
21. Lack of benefit from premedication for pegylated asparaginase during pediatric acute lymphoblastic leukemia/lymphoma therapy: A side-by-side comparison.
Menig S; Dinh A; Angus J; Tucker S; Leger KJ; Rushing T; Orgel E
Pediatr Blood Cancer; 2024 Jan; 71(1):e30716. PubMed ID: 37856184
[TBL] [Abstract][Full Text] [Related]
22. Peg-asparaginase for acute lymphoblastic leukemia.
Rytting M
Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
[TBL] [Abstract][Full Text] [Related]
23. Inadvertent intrathecal injection of PEG-asparaginase.
Naqvi A; Fadoo Z
J Pediatr Hematol Oncol; 2010 Jul; 32(5):416. PubMed ID: 20495483
[No Abstract] [Full Text] [Related]
24. Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study.
Albertsen BK; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Heyman M; Schmiegelow K
J Clin Oncol; 2019 Jul; 37(19):1638-1646. PubMed ID: 30978155
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the Frequencies of
Ali AM; Adam H; Hailu D; Howe R; Abula T; Coenen MJH
Appl Clin Genet; 2023; 16():131-137. PubMed ID: 37551203
[TBL] [Abstract][Full Text] [Related]
26. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
[TBL] [Abstract][Full Text] [Related]
27. Delayed-type hypersensitivity in response to L-asparaginase in a case of acute lymphoblastic leukemia.
Narazaki H; Kaizu K; Miyatake C; Koizumi S; Asano T; Fujino O
J Nippon Med Sch; 2012; 79(6):489-93. PubMed ID: 23291850
[TBL] [Abstract][Full Text] [Related]
28. Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review.
Abbott LS; Zakova M; Shaikh F; Shewaramani N; Punnett A; Dupuis LL
Paediatr Drugs; 2015 Aug; 17(4):315-21. PubMed ID: 25862348
[TBL] [Abstract][Full Text] [Related]
29. PEGylated
Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
[TBL] [Abstract][Full Text] [Related]
31. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
Hak LJ; Relling MV; Cheng C; Pei D; Wang B; Sandlund JT; Rubnitz J; Pui CH
Leukemia; 2004 Jun; 18(6):1072-7. PubMed ID: 15057247
[TBL] [Abstract][Full Text] [Related]
32. Predicting success of desensitization after pegaspargase allergy.
Swanson HD; Panetta JC; Barker PJ; Liu Y; Inaba H; Relling MV; Pui CH; Karol SE
Blood; 2020 Jan; 135(1):71-75. PubMed ID: 31750901
[No Abstract] [Full Text] [Related]
33. [Association of HLA-A, -B, -DRB1 alleles and haplotypes with acute lymphoblastic leukemia among ethnic Hans from northern China].
Qi J; Chen L; Wang T; Wang M; Wang X; Wu J; Ye S
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2017 Oct; 34(5):737-742. PubMed ID: 28981945
[TBL] [Abstract][Full Text] [Related]
34. Time Course and Management of Protracted Anaphylaxis Due to PEG-Asparaginase.
Fertal SA; Bradeen HA; Friesen E; Heath JL
J Pediatr Hematol Oncol; 2021 Apr; 43(3):e385-e387. PubMed ID: 32815880
[TBL] [Abstract][Full Text] [Related]
35. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
Toksvang LN; De Pietri S; Nielsen SN; Nersting J; Albertsen BK; Wehner PS; Rosthøj S; Lähteenmäki PM; Nilsson D; Nystad TA; Grell K; Frandsen TL; Schmiegelow K
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28423235
[TBL] [Abstract][Full Text] [Related]
36. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
Ettinger LJ; Kurtzberg J; Voûte PA; Jürgens H; Halpern SL
Cancer; 1995 Mar; 75(5):1176-81. PubMed ID: 7850718
[TBL] [Abstract][Full Text] [Related]
37. Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient.
Sahiner UM; Yavuz ST; Gökce M; Buyuktiryaki B; Altan I; Aytac S; Tuncer M; Tuncer A; Sackesen C
Pediatr Int; 2013 Aug; 55(4):531-3. PubMed ID: 23910807
[TBL] [Abstract][Full Text] [Related]
38. Safety of mRNA vaccination for COVID-19 in children with polyethylene glycol (PEG)-asparaginase allergy.
Doyle R; Melo M; Teoh C; Wen S; Willcocks S
Pediatr Allergy Immunol; 2023 Mar; 34(3):e13939. PubMed ID: 36974643
[No Abstract] [Full Text] [Related]
39. Hypersensitivity to different polyethylene glycol-containing products.
Khalid MB; Bundy V
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):734-735. PubMed ID: 33716148
[No Abstract] [Full Text] [Related]
40. Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia.
Petersen WC; Clark D; Senn SL; Cash WT; Gillespie SE; McCracken CE; Keller FG; Lew G
Pediatr Hematol Oncol; 2014 May; 31(4):311-7. PubMed ID: 24498943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]